• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding
    logo
    Zydus Wellness Ltd.
    21 Sep 2022
    10-year high
    2582.80
    1.21%
    Buy or sell: Vaishali Parekh of Prabhudas Lilladher recommends 2 stocks to buy today Sept 21
    Buy or sell: Vaishali Parekh of Prabhudas Lilladher recommends 2 stocks to buy today Sept 21
    livemint
    Vaishali Parekh of Prabhudas Lilladher has recommended two shares to buy today Zydus Life and Britannia Industries
    Copy LinkShare onShare on Share on Share on
    Zydus Wellness Ltd. has gained 33.03% in the last 1 Month
    logo
    Zydus Wellness Ltd.
    20 Sep 2022
    10-year high
    2582.80
    1.21%
    Zydus' US arm, BridgeBio Pharma get nod to sell drug for MoCD Type A disease in Europe
    Business Line
    MoCD Type A - an ultra-rare, life-threatening genetic disorder progresses rapidly in infants with survival age of about four years
    Copy LinkShare onShare on Share on Share on
    Mutual Funds have increased holdings from 11.61% to 18.39% in Jun 2025 qtr.
    logo
    Nestle India Ltd.
    20 Sep 2022
    ROE Outperformer
    1220.00
    -0.07%
    Nestle in talks to buy Yoga Bar stake
    Nestle in talks to buy Yoga Bar stake
    livemint
    Nestle India Ltd, the local unit of the world's largest food company, and other strategic and financial investors are in talks to buy a significant stake in nutritional snacks startup Yoga Bar, at least three people aware of the deal said
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors decreased from 902 to 873 in Jun 2025 qtr
    logo
    Hatsun Agro Products Ltd.
    19 Sep 2022
    908.05
    -0.24%
    Hatsun Agro Products board approves Rights Issue of 400 cr
    Hatsun Agro Products board approves Rights Issue of 400 cr
    livemint
    The issue will be available for existing shareholders. The eligible shareholders will be determined on the record date which the company will announce in due course.
    Copy LinkShare onShare on Share on Share on
    Hatsun Agro Products Ltd. has lost -26.11% in the last 1 Year
    logo
    Zydus Wellness Ltd.
    16 Sep 2022
    10-year high
    2582.80
    1.21%
    Zydus Lifesciences US arm gets tentative USFDA nod for Sugammadex injection
    Zydus Lifesciences US arm gets tentative USFDA nod for Sugammadex injection
    Business Standard
    Zydus Lifesciences Ltd on Friday said its US-arm has received tentative approval from the country's health regulator to market its generic version of Sugammadex injection. The injection is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery. The tentative approval granted by the US Food and Drug Administration (USFDA) to Zydus Pharmaceuticals (USA) Inc is for Sugammadex Injection of strengths 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL), single-dose vial, the company said in a regulatory filing. The drug will be manufactured at the group's injectables manufacturing facility at Jarod (Gujarat), India, it added. Sugammadex Injection had annual sales of USD 772 million in the US, the company said citing IQVIA MAT July 2022.
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors increased from 126 to 135 in Jun 2025 qtr.
    logo
    Zydus Wellness Ltd.
    13 Sep 2022
    10-year high
    2582.80
    1.21%
    Zydus gets USFDA nod to sell its cancer medicine in American market
    Zydus gets USFDA nod to sell its cancer medicine in American market
    Business Standard
    Zydus Lifesciences on Tuesday said it has received approval from the US health regulator to sell Lenalidomide capsules, used in the treatment of various types of cancers, in the American market. The company has received approval from the US Food and Drug Administration (USFDA) to market the product in strengths of 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg. Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders. The drug maker said the drug will be manufactured at the group's formulation facility at Ahmedabad SEZ. "We remain focused on providing patients access to affordable medication and USFDA approval of Lenalidomide Capsules, an important oncology therapy product, is yet another step in this endeavour," Zydus Lifesciences Managing Director Sharvil Patel stated. According to IQVIA MAT July data, Lenalidomide had annual sales of USD
    Copy LinkShare onShare on Share on Share on
    Zydus Wellness Ltd. has gained 31.16% in the last 3 Months
    logo
    Zydus Wellness Ltd.
    09 Sep 2022
    10-year high
    2582.80
    1.21%
    Zydus acquires rights to market MonoFerric injection in India, Nepal from Pharmacosmos A/S of Denmark
    Zydus acquires rights to market MonoFerric injection in India, Nepal from Pharmacosmos A/S of Denmark
    Moneycontrol
    MonoFerric is indicated for the treatment of iron deficiency in adult patients when oral iron preparations are ineffective or cannot be used or where there is a clinical need to deliver iron rapidly, the company said in a regulatory filing.
    Copy LinkShare onShare on Share on Share on
    Sharekhan increased Buy price target of Zydus Wellness Ltd. to 2688.0 on 03 Sep, 2025.
    Zydus acquires rights to market MonoFerric from Pharmacosmos A/S of Denmark
    Business Line | 09 Sep 2022 1 more
    Zydus acquires rights to market MonoFerric injection in India, Nepal
    Business Standard | 09 Sep 2022
    F
    Future Consumer Ltd.
    04 Sep 2022
    Board Meeting 52 week low
    0.43
    -2.27%
    Reliance Retail was Future Consumer's biggest customer in FY22
    Business Line
    Reliance Retail and FRL contributed 854.22 crore to its total revenue.
    Copy LinkShare onShare on Share on Share on
    Future Consumer Ltd. is trading below all available SMAs
    logo
    Zydus Wellness Ltd.
    02 Sep 2022
    10-year high
    2582.80
    1.21%
    Zydus Lifesciences, Lupin recall products in US market
    Zydus Lifesciences, Lupin recall products in US market
    Business Today
    According to the USFDA, the company's US-based unit is recalling the affected lot due to "Failed Impurities/Degradation Specifications".
    Copy LinkShare onShare on Share on Share on
    Zydus Wellness Ltd. is trading above all available SMAs
    logo
    Zydus Wellness Ltd.
    31 Aug 2022
    10-year high
    2582.80
    1.21%
    Zydus gets USFDA nod for generic version of Venlafaxine, Pregabalin
    Zydus gets USFDA nod for generic version of Venlafaxine, Pregabalin
    Business Standard
    Zydus Lifesciences Ltd on Wednesday said it has received final approval from the US health regulator to market its generic version of venlafaxine extended-release tablets used to treat depression. The company also said the US Food and Drug Administration (USFDA) has granted final approval for pregabalin extended-release tablets used to treat pain caused by nerve damage due to diabetes or shingles (herpes zoster) infection. The approval granted by the USFDA for venlafaxine extended-release tablets is for strengths of 37.5 mg, 75 mg, 150 mg and 225 mg, Zydus Lifesciences said in a regulatory filing. Venlafaxine is used to treat depression, anxiety, panic attacks and social anxiety disorder. It had annual sales of USD 46 million in the US, the company said citing IQVIA MAT July 2022. Further, Zydus Lifesciences said the final approval granted by the USFDA to market pregabalin extended-release tablets is for strengths of 82.5 mg, 165 mg and 330 mg. The drug had annual sales of USD 3 ..
    Copy LinkShare onShare on Share on Share on
    Zydus Wellness Ltd. has gained 33.03% in the last 1 Month
    Zydus Lifesciences gets USFDA nod for generic version of Venlafaxine, Pregabalin
    Business Line | 31 Aug 2022
    more
    loading
    Logo Trendlyne

    Stay ahead of the market

    Company

    PrivacyDisclaimerTerms of Use Contact Us

    Resources

    Blog FAQsStock Market Widgets

    Copyright © 2025 Giskard Datatech Pvt Ltd